# Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer

> **NCT01206881** · PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT01206881
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2011-07-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206881, "Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01206881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*